---
title: "Indivior PLC (LON:INDV) Insider Juliet Thompson Buys 3,850 Shares"
description: "Indivior PLC insider Juliet Thompson purchased 3,850 shares at an average price of GBX 1,388 ($18.90) on June 11th, totaling £53,438 ($72,754.25). Additionally, she bought 1,925 shares on the same day"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/244450696.md"
published_at: "2025-06-13T12:17:35.000Z"
---

# Indivior PLC (LON:INDV) Insider Juliet Thompson Buys 3,850 Shares

> Indivior PLC insider Juliet Thompson purchased 3,850 shares at an average price of GBX 1,388 ($18.90) on June 11th, totaling £53,438 ($72,754.25). Additionally, she bought 1,925 shares on the same day for £26,719 ($36,377.13). Indivior's stock opened at GBX 1,016 ($13.83) with a market cap of £1.59 billion. The company specializes in buprenorphine-based drugs for opioid dependence and related disorders.

Indivior PLC (LON:INDV - Get Free Report) insider Juliet Thompson acquired 3,850 shares of the firm's stock in a transaction on Wednesday, June 11th. The shares were acquired at an average price of GBX 1,388 ($18.90) per share, with a total value of £53,438 ($72,754.25).

Juliet Thompson also recently made the following trade(s):

-   On Wednesday, June 11th, Juliet Thompson bought 1,925 shares of Indivior stock. The stock was acquired at an average price of GBX 1,388 ($18.90) per share, with a total value of £26,719 ($36,377.13).

## Indivior Stock Performance

LON:INDV opened at GBX 1,016 ($13.83) on Friday. The firm has a market capitalization of £1.59 billion, a PE ratio of -842.41, a PEG ratio of -5.57 and a beta of 0.19. Indivior PLC has a 1 year low of GBX 548.71 ($7.47) and a 1 year high of GBX 1,349 ($18.37). The company has a current ratio of 0.83, a quick ratio of 1.52 and a debt-to-equity ratio of -170.06. The firm's fifty day simple moving average is GBX 834.55 and its 200 day simple moving average is GBX 845.69.

## Indivior Company Profile

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

## Further Reading

-   Five stocks we like better than Indivior
-   What is the Australian Securities Exchange (ASX)
-   Super Micro Computer Stock: Two Levels Smart Money Is Watching
-   Canada Bond Market Holiday: How to Invest and Trade
-   Fastenal Stock After Split: Poised for 5 More Years of Gains
-   What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
-   Gold and Commodities: Is the Bull Case Gaining Momentum?

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Indivior Right Now?

Before you consider Indivior, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.

While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [INDV.UK - Indivior PLC](https://longbridge.com/en/quote/INDV.UK.md)
- [INDV.US - Indivior Pharmaceuticals](https://longbridge.com/en/quote/INDV.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Indivior plc to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast | Indivior plc will announce its fourth quarter and full-year 2025 financial results on February 26, 2026, at 7:00 a.m. U. | [Link](https://longbridge.com/en/news/273985808.md) |
| Indivior Director David E. Wheadon Reports Acquisition of Common Shares | David E. Wheadon, Director of Indivior plc, has reported the acquisition of common shares in the company. The full filin | [Link](https://longbridge.com/en/news/271828514.md) |
| Indivior plc Files Initial Statement of Beneficial Ownership for CFO Ryan Preblick | Indivior plc has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commi | [Link](https://longbridge.com/en/news/271827739.md) |
| Indivior plc Files Initial Statement of Beneficial Ownership for Director Barbara Ryan | Indivior plc has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commi | [Link](https://longbridge.com/en/news/271828450.md) |
| Indivior plc Files Initial Statement of Beneficial Ownership for Director Juliet Thompson | Indivior plc has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission, li | [Link](https://longbridge.com/en/news/271828102.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
